Table 3 LC/MS analysis of main constituents of Shenmai injection fingerprint
From: Quality monitoring of Shenmai injection by HPLC pharmacodynamic fingerprinting
Peak | Identification | [M-H]−(m/z) | Fragment ion (m/z) |
|---|---|---|---|
3 | NotoginsenosideR1 | 931.5 | 799.5,637.4[M-H-Glc]−; 637.4[M-H- Glc-Xyl]−;475.4[M-H-Glc-Xyl-Glc]− |
4 | 20-Glc-ginsenoside-Rf | 961.5 | 799.7[M-H-Glc]−;653.3[M-H-2Glc]−;475.4[M-H-3Glc]− |
5,6,7 | NotoginsenosideR2 | 769.5 | 637.4[M-H-Xyl]−;475.4[M-H-Xyl-Glc]− |
8 | Ginsenoside-Re | 945.5 | 783.5[M-H-Rha]−;637.4[M-H-Rha-Glc]−;475.4[M-H-Rha-2Glc]− |
8 | Gnsenoside-Rg1 | 799.5 | 637.4[M-H-Glc]−;475.4[M-H-2Glc]− |
9 | Ginsenoside-Rf | 799.5 | 637.4[M-H-Glc]−;475.4[M-H-2Glc]− |
10 | Ginsenoside-Ra1/Ra2 | 1209.6 | 1047.5[M-H-Glc]−;901.4[M-H-Glc-Xyl]−;759.4[M-H-Glc-Xyl-Araf]− |
11 | Ginsenoside-Rb1 | 1107.6 | 945.5[M-H-Glc]−;783.5[M-H-2Glc]−;621.4[M-H-3Glc]−;459.6 [M-H-4Glc]− |
12 | Ginsenoside-Rb2 | 1078.6 | 945.5[M-H-Glc]−;783.5[M-H-2Glc]−; 621.4[M-H-3Glc]−;459.4 [M-H-3Glc-Arap]− |
13 | Ginsenoside-Rb3 | 1078.6 | 945.5[M-H-Glc]−;783.5[M-H-2Glc]−; 621.4[M-H-3Glc]−; 459.4 [M-H-3Glc-Xyl]− |
14 | Ginsenoside-Rd | 946.0 | 783.5[M-H-Glc]−;621.5[M-H-2Glc]−;459.6 [M-H-4Glc]− |
15 | Ginsenoside-Rg3 | 783.5 | 637.4 [M-H-Glc]−;475.4[M-H-2Glc]− |
16 | Ginsenoside-Rg6/F4 | 765.5 | 603.4 [M-H-Rha-H2O]−;457.5[M-H -Rha-Glc]− |
17,18,19 | Ginsenoside-Rh4 | 620.8 | 619.8 [M-H-Rha]−; 601.5[M-HRha-H2O];457.5[M-H -Rha-Glc]− |
20,21 | 20(R)-ginsenoside-Rg3 | 783.5 | 621.4[M-H-Glc]−;459.4[M-H-2Glc]− |
24,25 | 20-Glc-ginsenoside-Rf | 765.3 | 603.3[M-H-Glc]− |